Pharmaceuticals

The State of Things
12:36 pm
Tue May 6, 2014

Local Health Industry Changes

Assorted pharmaceuticals
Credit creative commons

Business Journal reporter Jason deBruyn talks about North Carolina parmaceutical companies

    

A recent deal between the biopharmaceutical companies GlaxoSmithKline and Novartis may mean more jobs and more attention for the Research Triangle. Plus, the $1.1 billion sale of Furiex pharmaceuticals increases possibilities for investment in the area. Meanwhile, Mooresville's Vestiq Holdings, a much smaller pharmaceutical company, is filing for bankruptcy. 

Read more
Business & Economy
8:05 am
Thu April 24, 2014

GlaxoSmithKline, Novartis, Lilly Part Of Drug Asset Swap

GSK Scientist. The company says much of its focus is on respiratory therapy and HIV drugs in RTP.
Credit www.gsk.com

Big changes and asset swaps in the pharmaceutical world are happening this week, but the Triangle should be spared of any fall-out.

One of the big moves in this chess game includes Switzerland-based Novartis agreeing to spend up to $16 billion for GlaxoSmithKline’s cancer drug business in Pennsylvania.

Read more
Shots - Health News
3:22 am
Mon December 30, 2013

$1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Originally published on Thu February 6, 2014 3:43 pm

Federal regulators this month opened a new era in the treatment of a deadly liver virus that infects three to five times more people than HIV. Now the question is: Who will get access to the new drug for hepatitis C, and when?

The drug Sovaldi will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long.

Read more
Toxicology
2:01 pm
Fri December 6, 2013

NC State's Database Could Revolutionize Pharmaceutical Research

The Comparative Toxicogenomics Database can be used to track information about toxic effects of therapeutic drugs.
Credit NC State University

North Carolina State University recently beefed up its toxicology database, which could help revolutionize pharmaceutical research.

NC State's Comparitive Toxicogenomics Database already cataloged the harmful health impacts of environmental chemicals, like arsenic. Then pharmaceutical giant Pfizer collaborated with the CTD to add unintended side effects of therapeutic drugs.

Read more
Health
4:38 pm
Fri September 13, 2013

Nursing Homes Significantly Reduce Rate of Antipsychotic Drug Use

Credit SalFalko / Flickr

North Carolina has reduced its rate of antipsychotic drug use in nursing homes by 23 percent over the last year-- that's the highest such improvement rate in the country.

Many nursing homes and adult care homes have been known to use antipsychotic drugs to help calm and control residents who have dementia. But overmedication can cause all sorts of problems for patients who are so drugged they can't participate in activities and who might fall because the drugs impair their coordination. Bob Konrad is a professor in health policy at UNC-Chapel Hill's School of Public Health.

Read more
Business & Economy
4:33 pm
Tue September 10, 2013

Walgreens To Buy NC's Kerr Drugstores

Kerr Drugstore in Hillsborough, NC.
Credit Wikipedia

The largest drugstore chain in the United States is buying out North Carolina-based Kerr Drug.

The banner on the Kerr Drug website says it’s North Carolina’s only hometown pharmacy.  But after more than 60 years, Kerr Drug is losing that designation. Walgreens announced today it’s acquiring Kerr’s drugstores and its specialty pharmacy business that fills prescriptions for chronic, complex treatments like cancer.

Michael Polzin is a spokesman for Walgreens, based in Illinois.

Read more
Business & Economy
4:11 pm
Wed August 14, 2013

Quintiles Acquires Triangle Research Group Novella

Credit Quintles

The Durham-based pharmaceutical company Quintiles is acquiring a Triangle research organization. 

Quintiles announced Wednesday it reached a deal with Novella Clinical in Morrisville.  Novella is an oncology and medical device research group with nearly 300 employees in the Triangle.  The companies did not release the terms of the deal. 

Read more
Business & Economy
4:15 pm
Fri July 26, 2013

Leaders Discuss How To Build NC's Biopharmaceutical Industry

RTP headquarters.
Credit Ildar Sagdejev

Leoneda Inge reports on Bio-Pharma discussion at GlaxoSmithKline.

GlaxoSmithKline hosted a gathering today in RTP for policy, non-profit and business leaders in the biopharmaceutical industry.

Jack Bailey, a Senior Vice President at GSK, says there are well over 100,000 North Carolinians working in the Life Sciences, 5,000 of them at his company.

“So it’s a very big important industry, it’s created a lot of jobs," Bailey says. "And really what we want to do today is start a discussion on how, at this great change in health care, we can make sure both federal, state and local policy decisions get made that continue to accelerate that innovation that comes out of companies like GSK.”

Read more
Business & Economy
10:48 am
Thu July 11, 2013

GlaxoSmithKline Executive In China Confesses To Paying Bribes

Credit GlaxoSmithKline

Authorities in China say a number of senior executives working for GlaxoSmithKline in that country have been placed under criminal investigation for suspected bribery and tax related violations.  The British pharmaceutical company's US headquarters are in Research Triangle Park. 

In an interview broadcast on WUNC, the BBC’s John Sudworth reported that the ministry of public security said the employees offered large bribes to officials, medical associations, hospitals and doctors to boost drug sales.

Read more
Business & Economy
8:12 am
Thu May 9, 2013

Quintiles Goes Public, Sets Share Price At $40

Credit Quintles

Leoneda Inge reports on Quintiles and trading on the NYSE.

Trading on the New York Stock Exchange begins Thursday for North Carolina-based Quintiles.

The company announced late Wednesday that it is selling about 23.7 million shares of its common stock to the public at $40 a share. That would raise nearly $950 million in this initial public offering for the bio-pharmaceutical services company.

Read more

Pages